ACTEMRA (tocilizumab)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+4
GENENTECH
Indication
Systemic-onset juvenile idiopathic arthritis
Systemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age. Read more about Systemic-onset juvenile idiopathic arthritis
12 drugs 8 manufacturers
Drugs that treat it
Common Systemic-onset juvenile idiopathic arthritis therapies.
ACTEMRA (tocilizumab)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+4
GENENTECH
ILARIS (canakinumab/PF)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals
ACTEMRA ACTPEN (tocilizumab)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+4
GENENTECH
ILARIS (PF) (canakinumab/PF)
ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals
TYENNE (tocilizumab-aazg)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
FRESENIUS KABI
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
BIOGEN-IDEC
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
BIOGEN/ORGANON
AVTOZMA (tocilizumab-anoh)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
CELLTRION USA,
Filter & compare in the drug finder →Opens the drug finder with Systemic-onset juvenile idiopathic arthritis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSystemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age.
Pathophysiologically categorized as an autoinflammatory disorder rather than a classical autoimmune disease, it is driven by dysregulated innate immune pathways and high levels of pro-inflammatory cytokines, notably interleukin-1 and interleukin-6.
Clinically, it is characterized by chronic or recurring arthritis accompanied by prominent systemic manifestations, including quotidian high-spiking fevers, an evanescent salmon-pink maculopapular rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis.
Patients are also at heightened risk for life-threatening complications, most notably macrophage activation syndrome.
- orpha.net
Systemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age Clinically, it is characterized by chronic or recurring arthritis accompanied by prominent systemic manifestations, including quotidian high-spiking fevers, an evanescent salmon-pink maculopapular rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis
- rheumatology.org
Systemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age
- hss.edu
Pathophysiologically categorized as an autoinflammatory disorder rather than a classical autoimmune disease, it is driven by dysregulated innate immune pathways and high levels of pro-inflammatory cytokines, notably interleukin-1 and interleukin-6
- nih.gov
Pathophysiologically categorized as an autoinflammatory disorder rather than a classical autoimmune disease, it is driven by dysregulated innate immune pathways and high levels of pro-inflammatory cytokines, notably interleukin-1 and interleukin-6 Clinically, it is characterized by chronic or recurring arthritis accompanied by prominent systemic manifestations, including quotidian high-spiking fevers, an evanescent salmon-pink maculopapular rash, generalized lymphadenopathy, hepatosplenomegaly, ...
- medicalnewstoday.com
Pathophysiologically categorized as an autoinflammatory disorder rather than a classical autoimmune disease, it is driven by dysregulated innate immune pathways and high levels of pro-inflammatory cytokines, notably interleukin-1 and interleukin-6
Personalize your experience
Follow Systemic-onset juvenile idiopathic arthritis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.